Bolt Biotherapeutics, Inc. (BOLT)
 NASDAQ: BOLT · Real-Time Price · USD
 5.58
 -0.18 (-3.12%)
  At close: Nov 3, 2025, 4:00 PM EST
5.75
 +0.17 (3.05%)
  After-hours: Nov 3, 2025, 5:12 PM EST
Bolt Biotherapeutics Employees
Bolt Biotherapeutics had 52 employees as of December 31, 2024. The number of employees decreased by 48 or -48.00% compared to the previous year.
Employees 
 52
Change (1Y) 
 -48
Growth (1Y) 
 -48.00%
Revenue / Employee 
 $80,135
Profits / Employee 
 -$975,250
Market Cap 
10.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 52 | -48 | -48.00% | 
| Dec 31, 2023 | 100 | 6 | 6.38% | 
| Dec 31, 2022 | 94 | 3 | 3.30% | 
| Dec 31, 2021 | 91 | 26 | 40.00% | 
| Dec 31, 2020 | 65 | - | - | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
BOLT News
- 4 weeks ago - Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 - GlobeNewsWire
 - 2 months ago - Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
 - 6 months ago - Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
 - 6 months ago - Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - GlobeNewsWire
 - 6 months ago - Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - GlobeNewsWire
 - 6 months ago - Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire
 - 7 months ago - Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire
 - 8 months ago - Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - GlobeNewsWire